Literature DB >> 16601379

Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer.

F Pinto1, T Prayer-Galetti, M Gardiman, E Sacco, M Ciaccia, S Fracalanza, G Betto, F Pagano.   

Abstract

INTRODUCTION: To identify risk factors for biochemical failure after radical prostatectomy (RP) in men with pathologically organ-confined (OC) prostate cancer (PCa).
MATERIALS AND METHODS: Clinical and pathological features of 350 consecutive patients with pathologically OC PCa treated only with RP and bilateral pelvic lymphadenectomy were analyzed, retrospectively, to identify predictor parameters of prostate-specific antigen (PSA) failure (PSA>or=0.4 ng/ml). The median follow-up was 58.6 months (range: 3.9-183 months). All pathological specimens were step sectioned at 4-mm intervals. Kaplan-Meier progression-free survival rates and chi2 test were adopted for statistical analyses. Multivariate Cox proportional hazard regression models were used to test the association between pathological Gleason score and surgical margin status.
RESULTS: 67 patients (19.1%) failed at a median follow-up of 40.2 months (range 1.9-123.3). Age and preoperative PSA failed to reveal significance also in patients with serum PSA>or=20 ng/ml (p=0.46). Patients with T3 clinical stage had a higher progression rate compared to T1C and T2 (43.5 vs. 27.8 and 17.3%, respectively) even if no high statistical significance was pointed out. Presence of perineural infiltration (p=0.04) and prostatic apex infiltration (p=0.74) in the prostatectomy specimens failed to reveal significance. A high pathological Gleason score (>or=7; p=0.0003) and surgical margin status (p<0.0001) were shown to be the most powerful predictive parameters of biochemical progression.
CONCLUSIONS: In patients with pathologically OC PCa the presence of a high pathological Gleason score and positive surgical margins appear to represent the most important factors for prediction of outcome following RP. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601379     DOI: 10.1159/000091619

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  14 in total

Review 1.  Percutaneous radiotherapy for low-risk prostate cancer: options for 2007.

Authors:  Dirk Bottke; Thomas Wiegel
Journal:  World J Urol       Date:  2007-02-15       Impact factor: 4.226

Review 2.  [Prevention of local recurrence using adjuvant radiotherapy after radical prostatectomy. Indications, results, and side effects].

Authors:  D Bottke; T Wiegel
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

3.  Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.

Authors:  Gunnar Lohm; Dirk Bottke; Basil Jamil; Kurt Miller; Konrad Neumann; Detlef Bartkowiak; Wolfgang Hinkelbein; Thomas Wiegel
Journal:  World J Urol       Date:  2012-03-30       Impact factor: 4.226

4.  Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.

Authors:  Alessandra Siegmann; Dirk Bottke; Julia Faehndrich; Gunnar Lohm; Kurt Miller; Detlef Bartkowiak; Thomas Wiegel; Wolfgang Hinkelbein
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

5.  A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP and implications for training.

Authors:  Carlo Gandi; Angelo Totaro; Riccardo Bientinesi; Filippo Marino; Francesco Pierconti; Maurizio Martini; Andrea Russo; Marco Racioppi; PierFrancesco Bassi; Emilio Sacco
Journal:  J Robot Surg       Date:  2022-02-28

6.  Radiotherapy after radical prostatectomy: immediate or early delayed?

Authors:  D Bottke; D Bartkowiak; M Schrader; T Wiegel
Journal:  Strahlenther Onkol       Date:  2012-11-07       Impact factor: 3.621

7.  Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.

Authors:  David J Hernandez; Matthew E Nielsen; Misop Han; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jonathan I Epstein
Journal:  Urology       Date:  2008-03-04       Impact factor: 2.649

8.  Postoperative radiotherapy after radical prostatectomy: indications and open questions.

Authors:  Pirus Ghadjar; Daniel Zwahlen; Daniel M Aebersold; F Zimmermann
Journal:  Prostate Cancer       Date:  2012-02-28

9.  How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.

Authors:  Nigel P Murray; Socrates Aedo; Cynthia Fuentealba; Eduardo Reyes; Omar Jacob
Journal:  Turk J Urol       Date:  2017-12-01

Review 10.  The role of postoperative radiotherapy in prostate cancer patients.

Authors:  Małgorzata Zarzycka; Ewa Ziółkowska; Tomasz Wiśniewski; Wiesława Windorbska; Agnieszka Zyromska; Zbigniew Wolski
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.